Phase I clinical trial results of verteporfin enhanced feeder vessel therapy in subfoveal choroidal neovascularisation in age related macular degeneration. 
INTRODUCTION
Choroidal neovascularization (CNV) is responsible for most of the severe vision loss associated with age-related macular degeneration (AMD). 1 The concept of treatment of subfoveal neovascular membranes in AMD by specifically targeting its feeder (afferent) vessel has been considered an attractive therapeutic approach in order to avoid collateral damage to larger retinal areas adjacent to and involving the fovea. [2] [3] [4] [5] [6] [7] The initial clinical success with absence of histopathologic data on treated choroidal neovascularization feeder vessels led to elaboration of a theoretical model of choriocapillaris blood flow and its relation with CNV. Previous studies also demonstrated that 22-42% of patients with CNV have demonstrable feeder vessels. 2, 3 A feeder vessel perfuses the choroidal neovascular membrane and can be distinguished from a draining vein by high speed ICG video angiography and timing. Published reports suggest that these vessels, when successfully photocoagulated by laser, produce reduction of the associated CNV blood flow. It has been reported that even partial occlusion of a feeder vessel may be sufficient to effectively reduce CNV blood flow and cause a favorable clinical response. 4 Various methods of laser feeder vessel obstruction have been employed including the 630 nm red, 1 the 576 nm yellow, 2, 7 the 514 nm argon green, Verteporfin enhanced…. 5 - nm diode laser 7, [10] [11] [12] and photodynamic therapy (PDT), normal light dose. 13 Feeder vessels are typically extrafoveal, and thus higher light doses (prolonged duration of treatment) may allow even more complete verteporfin mediated destruction of feeder vessels as collateral damage to overlying retina is less of a visual safety concern. In this FDA-approved pilot study we investigated the safety and efficacy of extrafoveal photodynamic therapy (PDT) occlusion of feeder vessels in patients with CNV due to AMD with escalation of light dose.
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SUBJECTS and METHODS

Patient population
This was a phase I/II light-dose escalating study approved by the Verteporfin enhanced…. 7 - greatest linear dimension of the entire lesion less than 5400 microns at the initial treatment. The patients had to be able to return for all study visits.
Excluded were the patients with hypersensitivity/allergy to fluorescein, ICG or verteporfin; with the FV located directly beneath a major retinal artery or vein; the patients unable to be photographed; or the patients with other ocular diseases associated with CNV (angioid streaks, pathologic myopia, histoplasmosis, blunt trauma, multifocal choroiditis). Additional exclusion criteria were pregnancy; prior PDT for minimally classic or occult with no classic CNV; and prior or ongoing treatment for AMD (macular scatter laser photocoagulation, subfoveal laser photocoagulation, transpupillary thermotherapy, radiation or pharmacotherapy).
Feeder Vessel Identification
At the baseline visit, all of the patients underwent a general ophthalmologic evaluation with dilated exam. Dynamic FA and ICG examinations were performed using the Heidelberg HRA I scanning laser ophthalmoscope (SLO) (Heidelberg Engineering, Heidelberg, Germany). The SLO is configured to record ICG fluorescence at a rate of 12 frames/second with a two second frame buffer. High-speed video ICG angiography was used to identify feeder vessels in the presence of CNV. The identification of feeder vessel(s) was based on their appearance preceding that of the retinal vessels during the early phases of Kozak et al.
Verteporfin enhanced…. 8 - dynamic FA and ICG and on their relationships with choroidal circulation and the CNV during the course of the angiography (Fig. 1a, 2a, 3a) . After the feeder vessel was identified on the H-S ICG the corresponding spot of area to be treated was transposed on to an early FA image to facilitate the location of laser delivery. The eligible patients were those with a single feeder vessel identified, and, therefore only one vessel was treated.
Treatment
The treatment procedure started with FDA approved dose intravenous 
RESULTS
The study included 9 eyes of 9 patients (5 men/4 women) with average age (mean±SD) 79.57±5.07 years. After the procedure we evaluated visual acuity and the degree of occlusion or reduction of perfusion of the feeder vessel by scanning laser video angiography, and the presence or change in late leakage from CNV on FA and visual acuity. Table 1 The first post-treatment video angiography showed that closure of the feeder vessel was achieved in 3 eyes (33.3%) (Fig.1b) , in 3 eyes (33.3%) the feeder vessel was hypoperfused (Fig.2b) and in 3 eyes (33.3%) feeder vessels Kozak et al.
Verteporfin enhanced…. 11 - were neither closed nor hypoperfused (Fig. 3b) . At the last follow up all FVs were reperfused (Figs. 1c, 2c, 3c) . The pre-and post-treatment area of fluorescein leakage on FA was 13.32 ± 10.33 mm 2 and 11.68 ± 8.62 mm 2 , respectively (p=.25). When eliminating the lowest energy dose there was a difference between pre-and post-treatment leakage area (p=.07).
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DISCUSSION
Photocoagulation of feeder vessels in AMD-associated CNV with different types of lasers resulted in various amounts and duration of anatomic and functional stabilization. 3, [5] [6] [7] 9 Feeder vessel closure initially used argon green and then yellow dye lasers in order to use a hemoglobin-absorbing wavelength to damage feeder vessels. Such photocoagulation caused full thickness retinal damage and choriocapillaris damage as well. 2, 3 Subsequently, the 810 nm diode laser was studied because of its ability to penetrate tissue and potentially spare the overlying retina. 7, 11 With this wavelength, vascular closure is difficult because the laser is poorly absorbed by hemoglobin 15 and coupling the laser with ICG as a desirable photosensitizing agent was suggested to make this modality more effective.
Photodynamic therapy has shown statistical benefit both in classic and occult choroidal neovascularization. 16, 17 Verteporfin therapy has vaso-occlusive mechanism that affects both the CNV and normal choroid. 18, 19 A single PDT application produces an area of hypofluorescence of the choriocapillaris, which at 1 week is identical in size to the area of the treatment spot used, consistent with a direct occlusive effect. However, clinical doses of PDT 20 and/or reduced light dose 21 leave the overlying RPE and the neurosensory retina undamaged.
Choroidal perfusion changes in the photosensitized area are considered transient, with restoration occurring within 3 months. 20, 22 As our study protocol included FA/ICG examination 1 month after the treatment, we could not evaluate Kozak et al.
Verteporfin enhanced…. 13 - this phenomenon at 1 week when choriocapillaris hypoperfusion is most prominent. A combination of PDT and subsequent FV laser coagulation using standard photocoagulation wavelengths has been used in the treatment of CNV in AMD 7, 13 and CNV secondary to choroidal rupture after blunt trauma. 23 We investigated the safety and efficacy of using PDT to directly occlude feeder vessels in subfoveal CNVs in patients with exudative AMD. There is only one similar case reported in the literature with report of visual improvement. 13 As we do not precisely know the amount of energy necessary for feeder vessel closure we chose a dose escalating study approach. We held the systemic drug dose and timing of the treatment the same.
In our group the most common FV pattern was its insertion in CNV membrane from the nasal side (the "racket-like pattern") (Figs.1a, 2b ) which is consistent with previous studies. 3 One patient had a vessel supplying CNV from the temporal side and in one (Fig. 3a) the vessel originated from the choroidal vascular bed directly beneath the CNV and was hidden by the membrane as soon as it was filled with dye (the "umbrella-like pattern"). The first examination after PDT treatment to the feeder vessels showed that patients in the first light dose group had no decrease in CNV perfusion after treatment; angiography revealed that the FVs remained perfused. In the second light dose group, we saw FV closure in 1 patient (Fig. 1b) and hypoperfusion in another and permanent closure in the last one. In the third dose, one patient had closed FV, one had hypoperfusion of FV (Fig. 3b) and the other, with an umbrella-like pattern feeder vessel, had no treatment effect. In the group with the highest light dose 1 patient Kozak et al.
Verteporfin enhanced…. 14 - had FV closure and 1 had no treatment effect. At the last follow-up FVs in all study patients were either still perfused or re-perfused.
Failure of FV closure after its laser photocoagulation has been previously reported. 3 The phenomenon of non-occlusion and/or reperfusion after PDT treatment is well known. Schmidt-Erfurth et al. showed that vessel occlusion after PDT is not complete and that the CNV complex remains patent at the FV level in 50% of treated patients. 18 Multiple PDT applications within short intervals have been shown to reduce the vessel patency in CNV but did not influence the frequency of recurrence of new vessels. Tomographic analysis also revealed loss of the superficial choriocapillaris layer and maintenance of perfusion of larger choroidal vessels. Based on these data it is tempting to speculate that a similar mechanism occurred in our patients in early post-treatment period.
Provided that high enough laser energy is used to occlude the FV there are other factors associated with blood supply to CNV, namely FV number and width. Even though strict inclusion criteria in this study included the presence of only one vessel, it is possible that CNV membranes were supplied by more than one feeder vessel. In a histopathologic study of choroidal neovascular membranes by Green et al. 54% of examined eyes had 2 or more vascular sources. 24 It is therefore very likely that in human CNV, smaller feeder vessels are present but are not angiographically visible.
Although we were able to only partially occlude the FVs as evidenced by We are not recommending this as a monotherapy for CNV. Our study was performed prior to the availability of anti-VEGF therapy for CNV. However, such modality seems to reduce the perfusion of the CNV complex and may be considered beneficial in combination with anti-VEGF or other pharmacotherapy. Pre-Tx ETDRS
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